Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)



Status:Recruiting
Conditions:HIV / AIDS, HIV / AIDS, HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:11/30/2018
Start Date:January 18, 2018
End Date:July 22, 2022
Contact:US GSK Clinical Trials Call Center
Email:GSKClinicalSupportHD@gsk.com
Phone:877-379-3718

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

The aim of the study is to establish if human immunodeficiency virus type 1 (HIV-1) infected
adult subjects with current virologic suppression on a ≥3-drug tenofovir alafenamide (TAF)
based regimen (TBR) remain suppressed upon switching to a two-drug regimen of dolutegravir
(DTG) 50 milligram (mg) + lamivudine (3TC) 300 mg. This study will also provide important
information regarding the safety and subject satisfaction with this two-drug regimen. The
primary objective of this trial is to demonstrate the non-inferior antiviral activity of
switching to DTG + 3TC once daily compared to continuation of TBR over 48 weeks in HIV-1
infected, ART-experienced, virologically suppressed subjects. This study also will
characterize the long-term antiviral activity, tolerability and safety of DTG + 3TC compared
to TBR through Week 144 and characterize the long-term antiviral activity, tolerability and
safety of DTG + 3TC through Week 200.

This will be a 200-week, Phase III, randomized, open-label, active-controlled, multicenter,
parallel-group study. The study will include a screening phase (up to 28 days), a randomized
early switch phase (Day 1 up to Week 148), a randomized late switch phase (Week 148 up to
Week 200), and a continuation phase (post Week 200). Approximately 550 HIV-1 infected adults
on stable TBR will be randomized 1:1 to switch to DTG + 3TC once daily for up to 200 weeks,
or to continue their TBR for 148 weeks, at which time and if HIV-1 ribonucleic acid (RNA) <50
copies per milliliter (c/mL) at Week 144, these subjects will switch to DTG + 3TC up to Week
200.


Inclusion Criteria:

- Subject must be able to understand and comply with protocol requirements,
instructions, and restrictions;

- Subject must be likely to complete the study as planned;

- Subject must be considered an appropriate candidate for participation in an
investigative clinical trial with medication (e.g. no active substance abuse, acute
major organ disease, or planned long-term work assignments out of the country).

- Aged 18 years or older (older where required by local regulatory agencies), at the
time of signing the informed consent.

- HIV-1 infected men or women.

- Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12
months prior to Screening: one within the 6 to 12 month window, and one within 6
months prior to Screening.

- Plasma HIV-1 RNA <50 c/mL at Screening.

- Must be on uninterrupted ART for at least 6 months prior to screening. Only the
following regimens are allowed:

- Subject on a TAF-based regimen for at least 6 months, or

- Subjects who switched from tenofovir disoproxil fumarate (TDF) (as part of
first-line regimen) to tenofovir alafenamide (TAF), without any changes to the
other drugs in their regimen, and have been on the TAF-based regimen for at least
3 months immediately prior to Screening. The switch must have occurred due to
tolerability/safety, access to medications, or convenience/simplification, and
must NOT have been done for suspected or established treatment failure.

- A female subject is eligible to participate if she is not pregnant (as confirmed by a
negative serum human chorionic gonadotrophin (hCG) test at screen and a negative urine
hCG test at randomization), not lactating, and at least one of the following
conditions applies:

a. Non-reproductive potential defined as:

- Pre-menopausal females with one of the following:

- Documented tubal ligation

- Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of
bilateral tubal occlusion

- Hysterectomy

- Documented bilateral oophorectomy

- Post-menopausal defined as 12 months of spontaneous amenorrhea [in questionable cases
a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol
levels consistent with menopause]. Females on hormone replacement therapy (HRT) and
whose menopausal status is in doubt will be required to use one of the highly
effective contraception methods if they wish to continue their HRT during the study.
Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status
prior to study enrolment.

b. Reproductive potential and agrees to follow highly effective methods for avoiding
pregnancy in females of reproductive potential (FRP) from 30 days prior to the first
dose of study medication and for at least 2 weeks after the last dose of study
medication.

- The investigator is responsible for ensuring that subjects understand how to properly
use these methods of contraception. All subjects participating in the study should be
counseled on safer sexual practices including the use and benefit/risk of effective
barrier methods (e.g., male condom) and on the risk of HIV transmission to an
uninfected partner.

- Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions of the consent form and the protocol. Eligible subjects
or their legal guardians must sign a written informed consent form before any
protocol-specified assessments are conducted.

Subjects enrolled in France must be affiliated to, or a beneficiary of, a social security
category.

Exclusion Criteria:

- Women who are breastfeeding or plan to become pregnant or breastfeed during the study.

- Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3
disease, EXCEPT cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical
or current CD4 cell counts less than 200 cells/millimeter (mm)^3 are NOT exclusionary.

- Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh
classification.

- Unstable liver disease (as defined by the presence of ascites, encephalopathy,
coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent
jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's
syndrome or asymptomatic gallstones).

- Evidence of Hepatitis B virus (HBV) infection based on the results of testing at
Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody
(anti-HBc), Hepatitis B surface antigen antibody (anti-HBs) and HBV deoxyribonucleic
acid (DNA) as follows: subjects positive for HBsAg are excluded; subjects negative for
anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA
are excluded.

Note: Subjects positive for anti-HBc (negative HBsAg status) and positive for anti-HBs
(past and/or current evidence) are immune to HBV and are not excluded. Anti-HBc must be
either total anti-HBc or anti-HBc immunoglobulin G (IgG), and NOT anti-HBc IgM.

- Anticipated need for any hepatitis C virus (HCV) therapy during the first 48 weeks of
the study, for HCV therapy based on interferon or for any drugs that have a potential
for adverse drug-drug interactions with study treatment throughout the entire study
period.

- Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without
clear documentation of treatment). Subjects who are at least 7 days post completed
treatment are eligible.

- History or presence of allergy or intolerance to the study drugs or their components
or drugs of their class.

- Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or
resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile
intraepithelial neoplasia.

- Subjects who in the investigator's judgment, poses a significant suicidality risk.

- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.

- Treatment with any of the following agents within 28 days of Screening: radiation
therapy; cytotoxic chemotherapeutic agents; any systemic immune suppressant.

- Exposure to an experimental drug or experimental vaccine within either 28 days, 5
half-lives of the test agent, or twice the duration of the biological effect of the
test agent, whichever is longer, prior to the first dose of investigational product
(IP).

- Use of any regimen consisting of single or dual ART.

- Any evidence of major nucleoside reverse transcriptase inhibitor (NRTI) mutation or
presence of any major INSTI resistance-associated mutation in any available prior
resistance genotype assay test result, if known.

- Any verified Grade 4 laboratory abnormality.

- Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN) or ALT ≥3
times ULN and bilirubin ≥1.5 times ULN (with >35% direct bilirubin).

- Creatinine clearance of <50 mL/minute/1.73 meter^2 via Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) method.

- Within the 6 to 12 month window prior to Screening and after confirmed suppression to
<50 c/mL, any plasma HIV-1 RNA measurement >200 c/mL.

- Within the 6 to 12 month window prior to Screening and after confirmed suppression to
<50 c/mL, 2 or more plasma HIV-1 RNA measurements ≥50 c/mL.

- Within 6 months prior to Screening and after confirmed suppression to <50 c/mL on
current ART regimen, any plasma HIV-1 RNA measurement ≥50 c/mL.

- Any drug holiday during the 6 months prior to Screening, except for brief periods
(less than 1 month) where all ART was stopped due to tolerability and/or safety
concerns.

- Any history of switch to another regimen, defined as change of a single drug or
multiple drugs simultaneously, due to virologic failure to therapy (defined as a
confirmed plasma HIV-1 RNA ≥400 c/mL.

- Subjects enrolled in France (or in other countries as required by local regulations or
Ethics Committee/Institutional Review Board [IRB]) who:

- Participated in any study using an investigational drug or vaccine during the
previous 60 days or 5 half-lives, or twice the duration of the biological effect
of the experimental drug or vaccine, whichever is longer, prior to screening for
the study, or

- Participate simultaneously in another clinical study.
We found this trial at
64
sites
Kansas City, Missouri 64128
Principal Investigator: Blair Thedinger
Phone: 877-379-3718
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Atlanta, Georgia 30341
Principal Investigator: Dennis M. Melton
Phone: 877-379-3718
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Cynthia C Brinson
Phone: 877-379-3718
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bakersfield, California 93309
Principal Investigator: Franco Anto Felizarta
Phone: 877-379-3718
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Bellaire, Texas 77401
Principal Investigator: Philip Carl Johnson
Phone: 877-379-3718
?
mi
from
Bellaire, TX
Click here to add this to my saved trials
Berkley, Michigan 48072
Principal Investigator: Paul Benson
Phone: 877-379-3718
?
mi
from
Berkley, MI
Click here to add this to my saved trials
Beverly Hills, California 90211
Principal Investigator: Anthony J. Scarsella
Phone: 877-379-3718
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: David K Stein
Phone: 877-379-3718
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Camden, New Jersey 08103
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Charlotte, North Carolina 28203
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Catherine Creticos
Phone: 877-379-3718
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75230
Principal Investigator: Mezgebe Berhe
Phone: 877-379-3718
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Darlinghurst, Sydney, New South Wales 2010
Phone: 877-379-3718
?
mi
from
Darlinghurst, Sydney,
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Anson K Wurapa
Phone: 877-379-3718
?
mi
from
Decatur, GA
Click here to add this to my saved trials
Desert Hot Springs, California 92262
?
mi
from
Desert Hot Springs, CA
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
Principal Investigator: Mehri S McKellar
Phone: 877-379-3718
?
mi
from
Durham, NC
Click here to add this to my saved trials
El Paso, Texas 79915
Principal Investigator: Ogechika Alozie
Phone: 877-379-3718
?
mi
from
El Paso, TX
Click here to add this to my saved trials
Fort Lauderdale, Florida 33308
Principal Investigator: Anthony LaMarca
Phone: 877-379-3718
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Pierce, Florida 34982
Principal Investigator: Moti N Ramgopal
Phone: 877-379-3718
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Cheryl Kay McDonald
Phone: 877-379-3718
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Greenville, North Carolina 27858
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Shannon R Schrader
Phone: 877-379-3718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntersville, North Carolina 28078
Principal Investigator: Frederick A. Cruickshank
Phone: 877-379-3718
?
mi
from
Huntersville, NC
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Samir Gupta
Phone: 877-379-3718
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Maleswari Ravi
Phone: 877-379-3718
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Kansas 66160
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Las Vegas, Nevada 89102
Principal Investigator: Alireza Farabi
Phone: 877-379-3718
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Long Beach, California 90813
Principal Investigator: Stefan Schneider
Phone: 877-379-3718
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California 90025
Principal Investigator: Anthony M Mills
Phone: 877-379-3718
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Lynchburg, Virginia 24501
Principal Investigator: Robert O Brennan
Phone: 877-379-3718
?
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Macon, Georgia 31201
Principal Investigator: Harold Katner
Phone: 877-379-3718
?
mi
from
Macon, GA
Click here to add this to my saved trials
Memphis, Tennessee 38120
Principal Investigator: Nehali Patel
Phone: 877-379-3718
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Hector Bolivar
Phone: 877-379-3718
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami Beach, Florida 33140
Principal Investigator: Michael B. Wohlfeiler
Phone: 877-379-3718
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Principal Investigator: William Keith Henry
Phone: 877-379-3718
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, New Jersey 07112
Principal Investigator: Jihad Slim
Phone: 877-379-3718
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Newport Beach, California 92663
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Howard Edelstein
Phone: 877-379-3718
?
mi
from
Oakland, CA
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Roberto Ortiz
Phone: 877-379-3718
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Karam Mounzer
Phone: 877-379-3718
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85012
Principal Investigator: Douglas Cunningham
Phone: 877-379-3718
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rialto, California 92337
Principal Investigator: Ryan Zane
Phone: 877-379-3718
?
mi
from
Rialto, CA
Click here to add this to my saved trials
Sacramento, California 95815
Principal Investigator: Jason A Flamm
Phone: 877-379-3718
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: David Prelutsky
Phone: 877-379-3718
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Leandro, California 94578
Principal Investigator: Dan Klein
Phone: 877-379-3718
?
mi
from
San Leandro, CA
Click here to add this to my saved trials
Sarasota, Florida 34232
Principal Investigator: Tanya Schreibman
Phone: 877-379-3718
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Savannah, Georgia 31405
Principal Investigator: Debbie P. Hagins
Phone: 877-379-3718
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Seattle, Washington 98109
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
Principal Investigator: Claudia Martorell
Phone: 877-379-3718
?
mi
from
Springfield, MA
Click here to add this to my saved trials
Syracuse, New York 13210
Principal Investigator: Elizabeth Reddy
Phone: 877-379-3718
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Cynthia A Mayer
Phone: 877-379-3718
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Toledo, Ohio 43608
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Torrance, California 90502
Principal Investigator: Eric Daar
Phone: 877-379-3718
?
mi
from
Torrance, CA
Click here to add this to my saved trials
Tulsa, Oklahoma 74105
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Washington, District of Columbia 20007
Principal Investigator: Gary L. Simon
Phone: 877-379-3718
?
mi
from
Washington,
Click here to add this to my saved trials
West Palm Beach, Florida 33409
Principal Investigator: Olayemi O Osiyemi
Phone: 877-379-3718
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Wilton Manors, Florida 33305
?
mi
from
Wilton Manors, FL
Click here to add this to my saved trials